arrow
J

Julien Lefranc

biotechnology and biological sciences research council (bbsrc)
H指数:14
被引数:1,319

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy

FEN1抑制在癌症治疗中单药疗法与联合疗法潜力的机制研究

2025-12-111
PRE
Discovery of ART5537: A Potent and Selective Small-Molecule Probe for EXO1
2025-12-010
PRE
Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy

用BAY 2416964靶向芳烃受体 (AhR): 一种用于癌症免疫治疗的选择性小分子抑制剂

2023-11-1412
OAAI
Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models
2020-06-0547
PREAI
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models
2020-01-03147
OAAI
Discovery of BAY-985, a Highly Selective TBK1/IKKε Inhibitor
2019-12-2031
PREAI
Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models
2017-07-018
PRE
High target binding affinity with long lasting cellular target engagement and high dose intermittent schedule of PI3K inhibitor copanlisib contribute to the potent anti-tumor activity and good safety profile
2017-07-010
PRE
Discovery and SAR of Novel 2,3-Dihydroimidazo[1,2-c]-quinazoline PI3K Inhibitors: Identification of Copanlisib (BAY 80-6946)

新型2,3-二氢咪唑并 [1,2-c]-喹唑啉PI3K抑制剂的发现和SAR: Copanlisib (BAY 80-6946) 的鉴定

2016-06-1698
OAAI